Protagonist Therapeutics, Inc. (PTGX)
92.25
+0.87
(+0.95%)
USD |
NASDAQ |
Dec 11, 16:00
92.24
0.00 (0.00%)
After-Hours: 20:00
Protagonist Therapeutics Cash from Investing (Quarterly): -58.56M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Johnson & Johnson | -542.00M |
| ADMA Biologics, Inc. | -14.37M |
| Regeneron Pharmaceuticals, Inc. | -402.90M |
| Vanda Pharmaceuticals, Inc. | 21.36M |
| Bristol Myers Squibb Co. | -1.702B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.937M |
| Cash from Financing (Quarterly) | 5.659M |
| Free Cash Flow | 63.71M |
| Free Cash Flow Per Share (Quarterly) | -0.0318 |
| Free Cash Flow to Equity (Quarterly) | -1.495M |
| Free Cash Flow to Firm (Quarterly) | -2.025M |
| Free Cash Flow Yield | 1.08% |